Britain and America have agreed to a key trade agreement that will ensure zero levies on British drug exports being sold in the American market.
The Terms of the Accord
Under the terms of the agreement, the UK has agreed to raise expenditure on drugs through the National Health Service (NHS). This pledge secures that tariffs on these vital goods will be held at nothing for a timeframe of 36 months.
This deal comes after previous warnings to significantly raise import taxes on patented drug imports, with potential rates discussed reaching double the cost.
"This arrangement between the UK strengthens the global environment for innovative medicines and establishes much-needed balance to transatlantic drug exports," a release noted.
Commercial Significance
Pharmaceuticals constitute one of the UK's most significant goods shipped to the United States, which is easily the largest buyer for large companies like GSK and AstraZeneca.
Export figures reveal that in the 12 months leading up to September, the UK shipped drugs totaling £11.1bn to the US. This amount represented nearly one-fifth of British export trade in that span.
"This deal protects jobs, stimulates capital expenditure and sets the stage for the UK to emerge as a global hub for medical research," the Business and Trade Secretary remarked.
Specific British Pledges
The agreement entails several key commitments from the UK:
- Higher Cost Ceiling: The UK will increase the cost ceiling at which it considers new therapies to be unaffordable by 25%.
- Boosted Medicine Funding: There is a goal to increase overall public funding on drugs from 0.3% of the national economy to 0.6% over the next decade.
- Refund Ceiling: The percentage drug companies must refund to the NHS to prevent overspending will be restricted at 15%. Previously, repayments topped 20%.
Broader Context
The deal comes amid a ongoing tension between the sector and the British authorities over drug pricing and NHS adoption.
These tensions were intensified by assertions that American consumers were charged a premium for the same drugs than patients in the Britain and the EU.
In recent months, several significant pharmaceutical investments in the UK have been paused or abandoned, while multi-billion-dollar expansions have been announced toward projects in the United States.
A senior figure publicly accepted that the NHS must increase expenditure on medicines, noting that its spending on drugs had shrunk as a share of its resources over the previous ten-year period.
